Principia Biopharma (PRNB) Knocks on Big Pharma’s Door
Principia Biopharma continued its impressive progress with its recent initial public offering on September 14, 2018. Principia Biopharma (Nasdaq: PRNB) has developed three drug candidates in immunology, central nervous system disorders, and oncology.
The company is utilizing 'Tailored Covalency,' its proprietary drug discovery platform, to discover new drugs that combine the dosing ability of an oral small molecule drug with the specificity of an antibody.
Standard small molecule drugs have a short duration of time that the drug binds to its target, called residence time, that require dosing regimens to maintain target concentration levels in the blood to get the desired result.
Principia has designed its drugs to remain bound to the target, and clear the body rapidly, to optimize residence time. According to the company this will minimize adverse effects while achieving the desired benefit.
PRN1008 is being developed for multiple autoimmune diseases. The Phase 2 study of PRN1008 for use in treating pemphigus, a chronic disorder that cause blisters and sores on the skin or mucous membranes, is forthcoming.
Principia has partnered with Sanofi SNY in an exclusive, global licensing agreement to develop and commercialize PRN2246 for multiple sclerosis. Sanofi paid Principia $40 million upfront and agreed to future milestone payments that have the potential to amount to $765 million on top of royalties.
The stock is down approximately 25% since its IPO which may be the result of post-IPO selloff and not a reflection of the company’s prospects. At $24.00 versus its opening day high of $32.65, Principia Biopharma might be occupying a price range opportunity for savvy investors.
IBB in +3.34% Uptrend, rising for three consecutive days on July 10, 2025
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IBB advanced for three days, in of 325 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on IBB as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IBB just turned positive on July 02, 2025. Looking at past instances where IBB's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 223 cases where IBB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for IBB moved out of overbought territory on July 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IBB broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health
Advertisement